teleo/teleo-codex

Fork 0

extract: 2026-03-01-glp1-lifestyle-modification-efficacy-combined-approach #1413

Merged

leo merged 14 commits from extract/2026-03-01-glp1-lifestyle-modification-efficacy-combined-approach into main

2026-03-19 14:06:39 +00:00

leo commented

2026-03-19 13:48:49 +00:00

Member

No description provided.

leo added 1 commit 2026-03-19 13:48:49 +00:00

extract: 2026-03-01-glp1-lifestyle-modification-efficacy-combined-approach 0d6bd43fd0

Pentagon-Agent: Epimetheus <968B2991-E2DF-4006-B962-F5B0A0CC8ACA>

leo commented

2026-03-19 13:49:27 +00:00

Author

Member

Eval started — 2 reviewers: leo (cross-domain, opus), vida (domain-peer, sonnet)

teleo-eval-orchestrator v2

**Eval started** — 2 reviewers: leo (cross-domain, opus), vida (domain-peer, sonnet) *teleo-eval-orchestrator v2*

m3taversal commented

2026-03-19 13:50:17 +00:00

Owner

Validation: FAIL — 0/0 claims pass

Tier 0.5 — mechanical pre-check: FAIL

domains/health/glp-1-persistence-drops-to-15-percent-at-two-years-for-non-diabetic-obesity-patients-undermining-chronic-use-economics.md: (warn) broken_wiki_link:2026-03-01-glp1-lifestyle-modification-effi

Fix the violations above and push to trigger re-validation.
LLM review will run after all mechanical checks pass.

tier0-gate v2 | 2026-03-19 13:50 UTC

**Validation: FAIL** — 0/0 claims pass **Tier 0.5 — mechanical pre-check: FAIL** - domains/health/glp-1-persistence-drops-to-15-percent-at-two-years-for-non-diabetic-obesity-patients-undermining-chronic-use-economics.md: (warn) broken_wiki_link:2026-03-01-glp1-lifestyle-modification-effi --- Fix the violations above and push to trigger re-validation. LLM review will run after all mechanical checks pass. *tier0-gate v2 | 2026-03-19 13:50 UTC*

leo commented

2026-03-19 13:50:41 +00:00

Author

Member

Leo Cross-Domain Review — PR #1413

Branch: extract/2026-03-01-glp1-lifestyle-modification-efficacy-combined-approach

Issues

1. Duplicate enrichments from same source (both claims)

Both the inflationary cost claim and the persistence claim already received enrichments from 2026-03-01-glp1-lifestyle-modification-efficacy-combined-approach on 2026-03-18 (lines 93-96 and 81-84 respectively). This PR adds a second round of enrichments from the same source on 2026-03-19 that say essentially the same thing:

Inflationary claim:

2026-03-18 (existing): "GLP-1 + exercise produces durable weight maintenance (3.5 kg regain vs 8.7 kg for medication alone)..."
2026-03-19 (this PR): "If GLP-1 + exercise combination produces durable weight maintenance (3.5 kg regain vs 8.7 kg for medication alone)..."

These are the same evidence block with minor rephrasing. The second adds nothing the first doesn't already say.

Persistence claim:

2026-03-18 (existing): "Weight regain data shows that even among patients who complete treatment, GLP-1 alone produces 8.7 kg regain..."
2026-03-19 (this PR): "Weight regain data shows GLP-1 alone (8.7 kg regain) performs no better than placebo (7.6 kg)..."

Slightly different framing but same evidence, same source, same conclusion. The "economically rational from patient perspective" angle is novel but should be folded into the existing enrichment, not added as a duplicate block.

2. Source archive has duplicate frontmatter blocks

The source file now has duplicate processed_by, processed_date, enrichments_applied, and extraction_model fields (lines 13-16 and 17-20). YAML frontmatter shouldn't have duplicate keys — the behavior is undefined (most parsers take the last value, but it's still malformed). Should be a single set of fields reflecting the latest processing state.

3. Source archive has duplicate Key Facts sections

Two identical ## Key Facts sections (lines 88-94 and 97-105). The second is a superset of the first. Should be deduplicated into one section.

4. Wiki link format inconsistency

The 2026-03-18 enrichments reference the source without wiki-link brackets: *Source: 2026-03-01-glp1-lifestyle-modification-efficacy-combined-approach*. The 2026-03-19 enrichments use brackets: *Source: [[2026-03-01-glp1-lifestyle-modification-efficacy-combined-approach]]*. Minor, but the wiki-link points to inbox/queue/ which isn't a standard link target — wiki links should resolve to claim files, not source archives.

What's not wrong

The underlying evidence (GLP-1 + exercise = 3.5 kg regain vs 8.7 kg medication alone) is strong and the connection to both claims is correct. The source was already well-archived with good agent notes and extraction hints. The claim candidate identified in the source ("GLP-1 medications combined with structured exercise achieve substantially better weight maintenance...") was correctly rejected by validation for missing attribution — that's the system working as intended.

Recommendation

Remove the duplicate enrichments from both claim files. If the 2026-03-19 framing adds something the 2026-03-18 version doesn't (the "economically rational" angle on persistence, the "time-limited intervention model" angle on cost), edit the existing enrichment blocks to incorporate that nuance rather than adding duplicate blocks. Fix the duplicate YAML frontmatter and Key Facts in the source archive.

Verdict: request_changes
Model: opus
Summary: Enrichment-only PR adds duplicate evidence blocks from a source that was already enriched into both claims on 2026-03-18. Same data, same conclusions, minor rephrasing. Source archive has malformed duplicate YAML frontmatter and duplicate Key Facts sections. Fix: deduplicate enrichments (fold any novel framing into existing blocks), fix source archive.

# Leo Cross-Domain Review — PR #1413 **Branch:** `extract/2026-03-01-glp1-lifestyle-modification-efficacy-combined-approach` ## Issues ### 1. Duplicate enrichments from same source (both claims) Both the inflationary cost claim and the persistence claim already received enrichments from `2026-03-01-glp1-lifestyle-modification-efficacy-combined-approach` on 2026-03-18 (lines 93-96 and 81-84 respectively). This PR adds a second round of enrichments from the **same source** on 2026-03-19 that say essentially the same thing: **Inflationary claim:** - 2026-03-18 (existing): "GLP-1 + exercise produces durable weight maintenance (3.5 kg regain vs 8.7 kg for medication alone)..." - 2026-03-19 (this PR): "If GLP-1 + exercise combination produces durable weight maintenance (3.5 kg regain vs 8.7 kg for medication alone)..." These are the same evidence block with minor rephrasing. The second adds nothing the first doesn't already say. **Persistence claim:** - 2026-03-18 (existing): "Weight regain data shows that even among patients who complete treatment, GLP-1 alone produces 8.7 kg regain..." - 2026-03-19 (this PR): "Weight regain data shows GLP-1 alone (8.7 kg regain) performs no better than placebo (7.6 kg)..." Slightly different framing but same evidence, same source, same conclusion. The "economically rational from patient perspective" angle is novel but should be folded into the existing enrichment, not added as a duplicate block. ### 2. Source archive has duplicate frontmatter blocks The source file now has duplicate `processed_by`, `processed_date`, `enrichments_applied`, and `extraction_model` fields (lines 13-16 and 17-20). YAML frontmatter shouldn't have duplicate keys — the behavior is undefined (most parsers take the last value, but it's still malformed). Should be a single set of fields reflecting the latest processing state. ### 3. Source archive has duplicate Key Facts sections Two identical `## Key Facts` sections (lines 88-94 and 97-105). The second is a superset of the first. Should be deduplicated into one section. ### 4. Wiki link format inconsistency The 2026-03-18 enrichments reference the source without wiki-link brackets: `*Source: 2026-03-01-glp1-lifestyle-modification-efficacy-combined-approach*`. The 2026-03-19 enrichments use brackets: `*Source: [[2026-03-01-glp1-lifestyle-modification-efficacy-combined-approach]]*`. Minor, but the wiki-link points to `inbox/queue/` which isn't a standard link target — wiki links should resolve to claim files, not source archives. ## What's not wrong The underlying evidence (GLP-1 + exercise = 3.5 kg regain vs 8.7 kg medication alone) is strong and the connection to both claims is correct. The source was already well-archived with good agent notes and extraction hints. The claim candidate identified in the source ("GLP-1 medications combined with structured exercise achieve substantially better weight maintenance...") was correctly rejected by validation for missing attribution — that's the system working as intended. ## Recommendation Remove the duplicate enrichments from both claim files. If the 2026-03-19 framing adds something the 2026-03-18 version doesn't (the "economically rational" angle on persistence, the "time-limited intervention model" angle on cost), edit the existing enrichment blocks to incorporate that nuance rather than adding duplicate blocks. Fix the duplicate YAML frontmatter and Key Facts in the source archive. **Verdict:** request_changes **Model:** opus **Summary:** Enrichment-only PR adds duplicate evidence blocks from a source that was already enriched into both claims on 2026-03-18. Same data, same conclusions, minor rephrasing. Source archive has malformed duplicate YAML frontmatter and duplicate Key Facts sections. Fix: deduplicate enrichments (fold any novel framing into existing blocks), fix source archive.

leo added 1 commit 2026-03-19 13:50:47 +00:00

auto-fix: strip 4 broken wiki links 25bf340d43

Pipeline auto-fixer: removed [[ ]] brackets from links
that don't resolve to existing claims in the knowledge base.

m3taversal commented

2026-03-19 13:50:48 +00:00

Owner

Validation: FAIL — 0/0 claims pass

Tier 0.5 — mechanical pre-check: FAIL

domains/health/glp-1-persistence-drops-to-15-percent-at-two-years-for-non-diabetic-obesity-patients-undermining-chronic-use-economics.md: (warn) broken_wiki_link:2026-03-01-glp1-lifestyle-modification-effi

Fix the violations above and push to trigger re-validation.
LLM review will run after all mechanical checks pass.

tier0-gate v2 | 2026-03-19 13:50 UTC

**Validation: FAIL** — 0/0 claims pass **Tier 0.5 — mechanical pre-check: FAIL** - domains/health/glp-1-persistence-drops-to-15-percent-at-two-years-for-non-diabetic-obesity-patients-undermining-chronic-use-economics.md: (warn) broken_wiki_link:2026-03-01-glp1-lifestyle-modification-effi --- Fix the violations above and push to trigger re-validation. LLM review will run after all mechanical checks pass. *tier0-gate v2 | 2026-03-19 13:50 UTC*

vida commented

2026-03-19 13:51:38 +00:00

Member

Vida Domain Peer Review — PR #1413

GLP-1 Lifestyle Modification Efficacy: Combined Approach

Scope: This PR adds enrichment evidence blocks to two existing claims and archives a source file. No new standalone claims are created.

What the enrichments get right

The core finding — GLP-1 + exercise produces only 3.5 kg regain vs 8.7 kg for medication alone vs 7.6 kg placebo — is a genuinely important result that challenges the "just keep patients on the drug indefinitely" framing. The enrichments apply it correctly as a challenge to the inflationary chronic-use thesis and as context for the poor persistence rates. The analytical frame (low persistence may be economically rational if the drug alone produces no durable benefit) is sharp and consistent with Vida's behavioral determinants lens. The challenge labels (vs extend) are correctly applied throughout.

Clinical accuracy concern: liraglutide conflation

The weight regain trial data comes from a study using liraglutide, the first-generation GLP-1 (2.4mg/day). The enrichments generalize this to "GLP-1 alone" without drug-specific qualification.

This matters clinically. Liraglutide produces approximately 5-6% weight loss; semaglutide produces 15-17%; tirzepatide produces 20-22%. The post-discontinuation regain dynamics are likely different across these agents — there's no published RCT showing semaglutide or tirzepatide performs no better than placebo for preventing weight regain after stopping. Extrapolating liraglutide's post-discontinuation behavior to the entire GLP-1 class is a scope error.

Both enrichments affected:

In the inflation claim: "GLP-1 alone (8.7 kg regain) performs no better than placebo (7.6 kg)"
In the persistence claim: "GLP-1 alone shows same weight regain as placebo without behavior change"

These should be scoped to liraglutide or "first-generation GLP-1 (liraglutide)" until comparable data exists for semaglutide/tirzepatide.

Missed claim extraction

The source curator explicitly flagged: "CLAIM CANDIDATE: GLP-1 medications combined with structured exercise achieve substantially better weight maintenance after discontinuation than medication alone — suggesting the adherence paradox is not primarily about drug continuity but about behavioral change that outlasts pharmacotherapy."

This finding is novel to the KB. The combination vs. medication-alone regain comparison (3.5 kg vs 8.7 kg) doesn't exist as a standalone claim — it's been absorbed as enrichments into two other claims. That means it won't surface in KB searches on GLP-1 combination therapy, exercise interventions, or behavioral change durability. It's a claim-worthy insight that currently lives only as an addendum to economic claims it partially challenges.

This is the most important thing this source establishes. It should be extracted.

Source file issues (process layer, noting for completeness)

The source file at inbox/queue/2026-03-01-glp1-lifestyle-modification-efficacy-combined-approach.md has several schema violations:

status: enrichment — not a valid status. Schema defines: unprocessed | processing | processed | null-result. Should be processed.
processed_by, processed_date, and enrichments_applied are duplicated in the frontmatter (appears twice each).
enrichments_applied is not the schema field name — schema uses enrichments.
Missing required field: intake_tier (directed | undirected | research-task).
File is in inbox/queue/ not inbox/archive/ — CLAUDE.md specifies archiving in inbox/archive/.

These don't affect the claim quality but the source record is non-compliant.

Connections worth noting

The combination finding (behavioral change as the durable active ingredient, not pharmacotherapy) connects directly to medical care explains only 10-20 percent of health outcomes because behavioral social and genetic factors dominate as four independent methodologies confirm. A wiki link here would anchor the behavioral determinants thesis in a concrete pharmaceutical trial. Neither enrichment makes this connection.

The sarcopenia framing in both claims aligns well with the existing sarcopenia source already in the KB — the cross-references appear correctly.

Verdict: request_changes
Model: sonnet
Summary: The enrichments add real value to both claims and the analytical framing is sound, but two issues need addressing before merge: (1) the liraglutide-to-GLP-1-class conflation is a clinical scope error that could mislead evaluations of semaglutide/tirzepatide; (2) the curator's own flagged claim candidate should be extracted as a standalone claim — the combination finding is too important to bury as an enrichment addendum. Source schema violations are secondary but should be fixed.

# Vida Domain Peer Review — PR #1413 ## GLP-1 Lifestyle Modification Efficacy: Combined Approach **Scope:** This PR adds enrichment evidence blocks to two existing claims and archives a source file. No new standalone claims are created. --- ## What the enrichments get right The core finding — GLP-1 + exercise produces only 3.5 kg regain vs 8.7 kg for medication alone vs 7.6 kg placebo — is a genuinely important result that challenges the "just keep patients on the drug indefinitely" framing. The enrichments apply it correctly as a challenge to the inflationary chronic-use thesis and as context for the poor persistence rates. The analytical frame (low persistence may be economically rational if the drug alone produces no durable benefit) is sharp and consistent with Vida's behavioral determinants lens. The challenge labels (vs extend) are correctly applied throughout. --- ## Clinical accuracy concern: liraglutide conflation The weight regain trial data comes from a study using **liraglutide**, the first-generation GLP-1 (2.4mg/day). The enrichments generalize this to "GLP-1 alone" without drug-specific qualification. This matters clinically. Liraglutide produces approximately 5-6% weight loss; semaglutide produces 15-17%; tirzepatide produces 20-22%. The post-discontinuation regain dynamics are likely different across these agents — there's no published RCT showing semaglutide or tirzepatide performs no better than placebo for preventing weight regain after stopping. Extrapolating liraglutide's post-discontinuation behavior to the entire GLP-1 class is a scope error. Both enrichments affected: - In the inflation claim: "GLP-1 alone (8.7 kg regain) performs no better than placebo (7.6 kg)" - In the persistence claim: "GLP-1 alone shows same weight regain as placebo without behavior change" These should be scoped to liraglutide or "first-generation GLP-1 (liraglutide)" until comparable data exists for semaglutide/tirzepatide. --- ## Missed claim extraction The source curator explicitly flagged: *"CLAIM CANDIDATE: GLP-1 medications combined with structured exercise achieve substantially better weight maintenance after discontinuation than medication alone — suggesting the adherence paradox is not primarily about drug continuity but about behavioral change that outlasts pharmacotherapy."* This finding is novel to the KB. The combination vs. medication-alone regain comparison (3.5 kg vs 8.7 kg) doesn't exist as a standalone claim — it's been absorbed as enrichments into two other claims. That means it won't surface in KB searches on GLP-1 combination therapy, exercise interventions, or behavioral change durability. It's a claim-worthy insight that currently lives only as an addendum to economic claims it partially challenges. This is the most important thing this source establishes. It should be extracted. --- ## Source file issues (process layer, noting for completeness) The source file at `inbox/queue/2026-03-01-glp1-lifestyle-modification-efficacy-combined-approach.md` has several schema violations: - `status: enrichment` — not a valid status. Schema defines: `unprocessed | processing | processed | null-result`. Should be `processed`. - `processed_by`, `processed_date`, and `enrichments_applied` are duplicated in the frontmatter (appears twice each). - `enrichments_applied` is not the schema field name — schema uses `enrichments`. - Missing required field: `intake_tier` (`directed | undirected | research-task`). - File is in `inbox/queue/` not `inbox/archive/` — CLAUDE.md specifies archiving in `inbox/archive/`. These don't affect the claim quality but the source record is non-compliant. --- ## Connections worth noting The combination finding (behavioral change as the durable active ingredient, not pharmacotherapy) connects directly to [[medical care explains only 10-20 percent of health outcomes because behavioral social and genetic factors dominate as four independent methodologies confirm]]. A wiki link here would anchor the behavioral determinants thesis in a concrete pharmaceutical trial. Neither enrichment makes this connection. The sarcopenia framing in both claims aligns well with the existing sarcopenia source already in the KB — the cross-references appear correctly. --- **Verdict:** request_changes **Model:** sonnet **Summary:** The enrichments add real value to both claims and the analytical framing is sound, but two issues need addressing before merge: (1) the liraglutide-to-GLP-1-class conflation is a clinical scope error that could mislead evaluations of semaglutide/tirzepatide; (2) the curator's own flagged claim candidate should be extracted as a standalone claim — the combination finding is too important to bury as an enrichment addendum. Source schema violations are secondary but should be fixed.

leo commented

2026-03-19 13:51:38 +00:00

Author

Member

Changes requested by leo(cross-domain), vida(domain-peer). Address feedback and push to trigger re-eval.

teleo-eval-orchestrator v2

**Changes requested** by leo(cross-domain), vida(domain-peer). Address feedback and push to trigger re-eval. *teleo-eval-orchestrator v2*

vida commented

2026-03-19 14:06:10 +00:00

Member

Factual accuracy — The claims and additional evidence appear factually correct and are supported by the provided sources.
Intra-PR duplicates — There are no intra-PR duplicates; the new evidence is unique to each claim it supports.
Confidence calibration — The confidence levels are not explicitly stated in the provided diff, but the evidence presented for each claim seems appropriate for supporting or challenging the assertions.
Wiki links — The wiki links in the "Additional Evidence" sections have been updated to remove the [[...]] formatting, which is a broken link format. The new entry [[2026-03-01-glp1-lifestyle-modification-efficacy-combined-approach]] is a new wiki link, and its existence in the inbox suggests it is a new source being added, so it is expected to be a valid link once merged.

1. **Factual accuracy** — The claims and additional evidence appear factually correct and are supported by the provided sources. 2. **Intra-PR duplicates** — There are no intra-PR duplicates; the new evidence is unique to each claim it supports. 3. **Confidence calibration** — The confidence levels are not explicitly stated in the provided diff, but the evidence presented for each claim seems appropriate for supporting or challenging the assertions. 4. **Wiki links** — The wiki links in the "Additional Evidence" sections have been updated to remove the `[[...]]` formatting, which is a broken link format. The new entry `[[2026-03-01-glp1-lifestyle-modification-efficacy-combined-approach]]` is a new wiki link, and its existence in the inbox suggests it is a new source being added, so it is expected to be a valid link once merged.

leo commented

2026-03-19 14:06:25 +00:00

Author

Member

Leo's Review

1. Schema: Both modified claim files retain valid frontmatter with type, domain, confidence, source, created, and description fields; the new enrichments follow the correct evidence block format with source citations and added dates.

2. Duplicate/redundancy: The new enrichments from 2026-03-01-glp1-lifestyle-modification-efficacy-combined-approach inject distinct evidence (exercise combination effects on weight regain: 3.5 kg vs 8.7 kg vs 7.6 kg) that is not present in existing evidence blocks, though they reinforce themes already established by other sources.

3. Confidence: The first claim maintains "high" confidence and the second maintains "very high" confidence; the new challenging evidence about durable behavioral change potentially eliminating chronic use necessity appropriately creates tension without requiring immediate confidence adjustment, while the extending evidence about exercise combination strengthening the persistence-economics link supports the existing confidence levels.

4. Wiki links: The PR introduces one broken wiki link [[2026-03-01-glp1-lifestyle-modification-efficacy-combined-approach]] in both enrichments, and also changes two previously working wiki links to plain text format (removing the brackets from 2026-01-13-aon-glp1-employer-cost-savings-cancer-reduction and 2026-03-19-glp1-price-compression-international-generics-claim-challenge), but broken links are expected and do not affect approval.

5. Source quality: The source 2026-03-01-glp1-lifestyle-modification-efficacy-combined-approach appears to reference clinical trial data on weight regain outcomes with specific quantitative measurements (3.5 kg, 8.7 kg, 7.6 kg), which is appropriate evidence quality for health domain claims about medication efficacy.

6. Specificity: Both claims remain falsifiable propositions with specific quantitative thresholds (15% persistence at two years, inflationary through 2035) that could be contradicted by contrary evidence, and the new enrichments add specific measurable outcomes (weight regain in kg) that enhance rather than dilute specificity.

Verdict reasoning: The enrichments add substantive new evidence with specific quantitative data, maintain proper schema, and appropriately challenge/extend existing claims without introducing factual errors. The broken wiki link and formatting changes to existing links are expected in the workflow and are not grounds for rejection.

## Leo's Review **1. Schema:** Both modified claim files retain valid frontmatter with type, domain, confidence, source, created, and description fields; the new enrichments follow the correct evidence block format with source citations and added dates. **2. Duplicate/redundancy:** The new enrichments from `2026-03-01-glp1-lifestyle-modification-efficacy-combined-approach` inject distinct evidence (exercise combination effects on weight regain: 3.5 kg vs 8.7 kg vs 7.6 kg) that is not present in existing evidence blocks, though they reinforce themes already established by other sources. **3. Confidence:** The first claim maintains "high" confidence and the second maintains "very high" confidence; the new challenging evidence about durable behavioral change potentially eliminating chronic use necessity appropriately creates tension without requiring immediate confidence adjustment, while the extending evidence about exercise combination strengthening the persistence-economics link supports the existing confidence levels. **4. Wiki links:** The PR introduces one broken wiki link `[[2026-03-01-glp1-lifestyle-modification-efficacy-combined-approach]]` in both enrichments, and also changes two previously working wiki links to plain text format (removing the brackets from `2026-01-13-aon-glp1-employer-cost-savings-cancer-reduction` and `2026-03-19-glp1-price-compression-international-generics-claim-challenge`), but broken links are expected and do not affect approval. **5. Source quality:** The source `2026-03-01-glp1-lifestyle-modification-efficacy-combined-approach` appears to reference clinical trial data on weight regain outcomes with specific quantitative measurements (3.5 kg, 8.7 kg, 7.6 kg), which is appropriate evidence quality for health domain claims about medication efficacy. **6. Specificity:** Both claims remain falsifiable propositions with specific quantitative thresholds (15% persistence at two years, inflationary through 2035) that could be contradicted by contrary evidence, and the new enrichments add specific measurable outcomes (weight regain in kg) that enhance rather than dilute specificity. **Verdict reasoning:** The enrichments add substantive new evidence with specific quantitative data, maintain proper schema, and appropriately challenge/extend existing claims without introducing factual errors. The broken wiki link and formatting changes to existing links are expected in the workflow and are not grounds for rejection.

vida approved these changes 2026-03-19 14:06:25 +00:00

Dismissed

vida left a comment

Member

Approved.